Visiongain Report Looks at Opportunities Within the $6.3bn Anti-Obesity Drugs Market

Wednesday, December 5, 2018 Obesity News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, December 5, 2018 /PRNewswire/ --

Global Anti-Obesity Drugs Market Forecast 2018-2028 

Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

 

     (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

The global anti-obesity drugs market was is valued at $1.3bn in 2017 and is expected to grow at a CAGR of 29.1%

from 2017 to 2022. In 2017, the prescription drugs submarket held 96% of the global anti-obesity drugs market.

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 119 tables and 139 figures- all unavailable elsewhere.

The 250-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global Anti-obesity Drugs Market forecast from 2018-2028

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action: • Incretion mimetics/GLP-1 agonists • SNDRIs • Lipase Inhibitors • Serotonin receptor agonists • Sympathomimetic-GABA receptor agonists • Sympathomimetics

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Duration of Therapy: • Long-term Drugs • Short-term Drugs

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Innovator vs Generic Drugs: • Innovator • Generic Drugs

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Prescription vs OTC: • Prescription Drugs • OTC

• This report discusses and provides revenue forecasts from 2018-2028 for selected anti-obesity drugs: • Saxenda • Contrave/Mysimba • Belviq • Qysmia • Xenical • Alli

• This report provides individual revenue forecasts from 2018-2028 for these regional and national markets: • US • Japan • EU5: Germany, France, Spain, Italy, UK • BRIC: Brazil, Russia, China, India • RoW

Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs

• Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market: • Eisai/Arena • GlaxoSmithKline (GSK) • Novo Nordisk • Orexigen/Takeda • Roche • Teva • Vivus

• This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.

• This report gives an overview of pricing and reimbursement in the US and EU.

• This report provides a SWOT Analysis of the global anti-obesity drugs market.

Visiongain's study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-anti-obesity-drugs-market-forecast-2018-2028/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.

ADial Pharmaceuticals AEMPS AIFA HAS Akrimax Pharmaceuticals American Medical Association Arena Pharmaceuticals AstraZeneca Biophytis Boehringer Ingelheim Boston Therapeutics Diasome Eisai EMEA Empros Pharma FDA G-BA GenePreDiT GlaxoSmithKline (GSK) Hanmi Ildong Pharmaceuticals Intarcia Therapeutics Ionis Pharmaceuticals Janssen Pharmaceuticals KT&G Life Sciences KVK Tech Kwang Dong Medivation Medlab Clinical Neothetics NGM Biopharmaceuticals NICE SMC Novartis Novo Nordisk OPKO Health Orexigen Rhythm Pharmaceuticals Roche Saniona Shionogi & Co., Ltd Takeda Teva Valeant Pharmaceuticals Virtici Vivus World Health Organization (WHO) Xenetic Biosciences Zafgen

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

SOURCE Visiongain



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store